


1/14

FIG. 1(a)



300 Base pair
↑

The PAX2 expression in 3 out of 5 channel TURP specimens.

- Lane 1 negative control (water)
- Lane 2-6 channel TURPs (i.e prostate cancers)
- Lane 7 positive control (OUK 117)

- blank lanes

Fig. 1(a)

2/14

GAPDH Expression in the 5 Channel TURPs




Fig. 1(b)

Lane 1-5 Channel TURP 1 to 5
 Lane 7 Negative control (water)
 Lanes - Blank

3/14

Lack of expression of PAX 2 in 10 Benign Prostatic \Hypertrophy specimens




Fig. 2(a)


Lanes 1-10: the 10 benign prostatic hypertrophy specimens
 lane 11: Positive control (UOK 117)
 Lane 12: negative control (water)
 Lanes 13-14: Blank

GAPDH RTPCR of the 10 Benign Prostatic Hypertrophy specimens

WO 00/49175

PCT/GB00/00586


4/14



Lanes 1-10: Ten Benign samples
 Lane 11: Negative control (water)
 Lanes 12-14: Blank lanes


Fig. 2(b)

5/14

*Fig. 3(a)*

6/14


GAPDH RTPCR of the Cell Lines




Lane 1: LNCaP
 Lane 2: DU145
 Lane 3: PC3
 Lanes -: Blank
 Lane 5: Negative Control (water)

Fig. 3(b)

Expression of PAX2 in tumours 1,3,7,14,16,19,21,25,26.



The Lanes are marked with the number given to each tumour. UOK117 is the positive control. Water is the negative control.




Southern hybridisation of the above gel

Fig. 4(a)

8/14

Expression of PAX2 in tumours 24,27,32,38,41 and 43.




The Lanes are marked with the number given to each tumour. UOK117 is the positive control. Water is the negative control.

Fig. 4(b)

9/14

GAPDH expression in tumours 24,27,32,38,41 and 43




200 Base pair

The Lanes are marked with the number given to each tumour.
Water is the negative control.


Fig. 4(c)

10/14


A1.



A2.



B1.



B2.





Fig. 5A


09933948.000001

11/14


A1.



A2.



B1.



B2.





Fig. 5B

05933548.000001

PAX2 Expression in Prostate Cancer



- 14/27 (52%) of prostate cancers express PAX2

Fig. 5A3

13/14




Fig. 5C

14/14





Fig. 5D

SUBSTITUTE SHEET (RULE 26)

09933543.082004